The future of monoclonal antibody engineering.
Renner
C
C
Med. Dept. I, Saarland University Medical School, Homburg/Saar, Germany. incren@med-rz.uni-sb.de
Hartmann
F
F
Pfreundschuh
M
M
D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D015195:Drug Design; D005544:Forecasting; D005803:Genes, Immunoglobulin; D006801:Humans; D007135:Immunoglobulin Variable Region / Q000235:genetics / Q000276:immunology; D008223:Lymphoma / Q000175:diagnosis / Q000276:immunology / Q000532:radiotherapy / Q000628:therapy; D015202:Protein Engineering / Q000639:trends; D016499:Radioimmunotherapy; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D000911:Antibodies, Monoclonal; D007135:Immunoglobulin Variable Region; D011993:Recombinant Fusion Proteins